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Abstract
Modulation of the antitumor immune response through the engagement of NKG2D receptors with their ligands (L)
on targets represents a promising therapeutic approach against cancer. In this study, we tested the effect of
valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, on the expression of NKG2D ligands in myeloma cells.
We demonstrated that VPA was able to upregulate both protein and mRNA expression of major histocompatibility
complex class I–related chain (MIC) A/B and UL16-binding protein (ULBP) 2 without any significant effect on the
expression of ULBP1, ULBP3, and ULBP4 or induction of other natural killer (NK) cell ligands, such as NKp30-L,
NKp44-L, and NKp46-L in myeloma cells. A 51Cr release assay and degranulation assay indicated that the induction
of MICA/B and ULBP2 augmented NK cell–mediated lysis of myeloma cells, which was abolished by the addition
of a blocking NKG2D antibody. Activation of constitutively phosphorylated extracellular signal–regulated kinase
(ERK) by VPA is essential for the up-regulation of MICA/B and ULBP2 expressions. Inhibition of ERK using ERK
inhibitor PD98059 decreased both MICA/B and ULBP2 expressions and NK cell cytotoxicity. Furthermore, over-
expression of constitutively active ERK in ARK resulted in increased MICA/B and ULBP2 expressions and enhanced
NK cell lysis. These data indicate that increased sensitivity of VPA-treated myeloma cells to NK cell lysis is caused
by higher NKG2D ligand expression, resulting from more active ERK signaling pathway. Our results provide evi-
dence that targeting ERK signaling pathway may be an additional mechanism supporting the antimyeloma activity
of HDAC inhibitors and suggest its possible immunotherapeutic value for myeloma treatment.
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Introduction
Multiple myeloma (MM) is a plasma cell malignancy characterized
by neoplastic accumulation of clonal secretory plasma cells in the
bone marrow [1]. Recently, significant advances have been made
by combining the immunomodulatory drugs as well as the protea-
some inhibitors with autologous peripheral blood stem cell trans-
plantation, which allows for long-term disease-free survival in the
majority of transplant-eligible patients. However, MM still remains
largely incurable with current therapeutic strategies [2]. The majority
of patients with MM relapse with an average survival time of 4 to
7 years. These poor results led to the search for alternative treatment
strategies such as adoptive natural killer (NK) cell transfer or other
novel pharmaceuticals.
NK cells, as part of the innate immunity, substantially contribute
to the elimination of virus-infected cells as well as antitumor immune
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response [3]. NK cell activity is tightly regulated by a delicate balance
between inhibitory and activating receptors that recognize ligands (L)
on target cells [4]. Among the activating receptors involved in NK
cell–mediated cytotoxicity, NKG2D is a C-type lectin-like activating
receptor and expressed by NK cells, γ/δ T cells, and CD8+ T cells in
humans. NKG2D recognizes its ligands major histocompatibility
complex class I–related chain (MIC) A, MICB, and UL16-binding
proteins (ULBP) 1 to 4 in humans [5,6]. These NKG2D ligands are
almost not expressed in normal cells. However, they are constitu-
tively expressed in many malignant cells, such as those in colon, liver,
ovary, and hematological malignancies [7–11], and are upregulated
on cellular stress, cell transformation, and viral infection [12,13].
The efficiency of NKG2D-mediated cytotoxicity by NK cells has
been shown to correlate with the expression levels of NKG2D ligands
on target cells [10]. Thus, the modulation of the interaction between
NKG2D and its ligands is thought to play an important role in tumor
rejection and surveillance.
Characterized by their anticancer properties, histone deacetylase
(HDAC) inhibitors have recently attracted much attention. HDAC
inhibitors induce an increased acetylation of DNA-associated histone
proteins, leading to cell cycle arrest, redifferentiation, and apoptosis
in a broad range of malignant cells [8]. With a favorable pharmaco-
logic profile and well-tolerated side effects, the well-known anti-
epileptic drug valproic acid (VPA) has been demonstrated to mediate
HDAC inhibition and to display antineoplastic activity safely in vivo
[14]. In addition, VPA has been found to sensitize tumor cells to
NK cell–mediated lysis dependent on NKG2D signaling [15,16].
Increased NK cell–mediated lysis after VPA treatment was initially
found in neuroblastoma cells [17]. This result was later confirmed in
hepatoma cells and leukemic cells [8,16]. These data suggest that VPA
might be a valuable new and tumor-selective drug by enhancing
immune surveillance for treatment of MM.
In this study, we investigated the potential role of NKG2D in
immune surveillance against MM by analyzing expressions of the
various NKG2D ligands on panels of myeloma cell lines and patient
myeloma cells after treatment with VPA, thus evaluating its impact
on recognition of tumor cells by cytotoxic effectors. We show that
treatment of human myeloma cells with VPA upregulates expression
of NKG2D ligand, leading to a significantly increased NK cell–
mediated lysis of tumor cells due to enhanced NKG2D engagement.
Constitutively active phosphorylated extracellular signal–regulated
kinase (pERK) but not pAKT by VPA is essential for the up-regulation
of NKG2D ligand in myeloma cells. Therefore, VPA in combination
with adoptive NK cell transfer as a new treatment option might be
especially useful for control of residual minimal disease by increasing
susceptibility of myeloma cells to immune surveillance.
Materials and Methods
Cell Culture
ARK, OPM2, and OCI-MY5 myeloma cell lines were obtained
from American Type Cell Collection (ATCC, Manassas, VA) and
were cultured in RPMI 1640 medium (Invitrogen, Frederick,
MD) supplemented with 10% FBS (Invitrogen) and 1% penicillin
streptomycin–glutamine in an atmosphere of 5% carbon dioxide at
37°C. Peripheral blood samples and bone marrow samples were
obtained from patients and healthy donors. The institutional review
board of Tongji University School of Medicine approved these
research studies and all subjects provided written consent approving
use of their samples for research purposes. CD56+/CD3− NK cells
and CD138+ myeloma cells were isolated from peripheral blood
and bone marrow using magnetic bead selection (Miltenyi Biotech,
Auburn, CA). All selected cells were more than 94% pure.
Reagents and Antibodies
Histone deacetylase inhibitor VPA was purchased from Sigma-
Aldrich (Shanghai, China). Cell surface protein expression was deter-
mined by standard flow cytometry using unconjugated or fluorescein
isothiocyanate (FITC)–, phycoerythrin (PE)–, and allophycocyanin
(APC)–conjugated antibodies (Abs) to CD3, CD56, CD138,
MICA/B (BD Pharmingen, San Diego, CA), ULBP1 to ULBP4,
CD48, CS1, CD155, CD112, CD28, AICL(CLEC2B), LFA-3
(CD58; R&D Systems, Minneapolis, MN). Annexin V and 7AAD
were from BD Pharmingen. The recombinant (r) NKp30/human
IgG1 Fc chimera, rNKp44/human IgG1 Fc chimera, and rNKp46/
human IgG1 Fc chimera were purchased from R&D Systems. Human
IgG was purchased from Caltag Laboratories (Burlingame, CA). The
procedure for staining cells with Ig fusion proteins has been described
[18]. The blocking anti-NKG2D monoclonal antibody (mAb) and
mouse IgG1 were purchased from R&D Systems. The following pri-
mary Abs were used forWestern blot analysis: p44/42 mitogen-activated
protein kinases (MAPK) (ERK1/2), anti–phospho-ERK1/2, AKT, anti–
phospho-AKT (Ser473; Cell Signaling, Beverly,MA),MICA/B,ULBP1
toULBP4 (R&DSystems), and polyclonal β-actin (Sigma-Aldrich). The
ERK inhibitor PD98059was from Calbiochem (Darmstadt, Germany).
Flow Cytometry
Cell surface expression of protein was tested using flow cytometry.
Cells were washed twice with cold phosphate-buffered saline (PBS) and
stained with indicated unconjugated or FITC-, PE-, APC-conjugated
Abs or isotype Ab for 30 minutes at 4°C. After incubation for 30 min-
utes at 4°C, cells were washed three times with PBS and suspended
in PBS. Samples were examined on a flow cytometer (FACSCalibur;
Becton Dickinson Medical Devices, Shanghai, China), and the
data were analyzed using FCS Express 3 Flow Cytometry software
(De Novo Software, Los Angeles, CA). In all experiments, cells were
analyzed for NKG2D ligand expression or other NK cell ligand expres-
sion by gating on annexin V and 7AAD double negative cells.
Western Blot Analysis
Cells were collected and resuspended in lysis buffer [30mMTris-HCl
(pH7.5), 150mM sodium chloride, 1mMphenylethylsufonyl fluoride,
5mMEDTA, 1%NP-40, 1mM sodium orthovanadate, and 10mg/ml
aprotinin] for 15 minutes at 4°C. The suspension was then vortexed
and centrifuged at 10,000g for 10 minutes. The supernatant was
collected and mixed with an equivalent volume of 2× protein loading
buffer containing 2-mercaptoethanol and boiled for 5 minutes before
loading onto sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis. Upon completion of electrophoresis, proteins were transferred onto
nitrocellulose membranes and blotted against primary Abs for 1 hour at
room temperature. Membranes were washed with PBS (pHzz 7.4) con-
taining 0.05%Tween-20 and incubated with HRP-conjugated second-
ary Ab for 1 hour. Protein bands were visualized by enhancing
chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ).
β-Actin was used to normalize the amount of protein in each sample.
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RNA Extraction and Real-time Polymerase Chain Reaction
Total RNA was extracted using TRIzol reagent (Invitrogen) follow-
ing the manufacturer’s instructions. The quality and concentration of
the extracted RNA were determined by measuring light absorbance at
260 nm (A260) and calculating the A260/A280 ratio. A measure of 2-μg
sample of total RNA was then reverse transcribed into cDNA. One
microliter of cDNA was then subjected to polymerase chain reaction
(PCR) using specific primers. To internally standardize the levels of
gene expression, we used the β-actin housekeeping gene. Amplifi-
cations were performed with the ABI PRISM 7000 Sequence Detec-
tion System in a 50-μl final volume using 40 cycles of a two-step PCR
(15 seconds at 94°C and 60 seconds at 60°C) after initial denaturation
(95°C for 15 minutes). The primer sequences are given as follows:
MICA sense, 5′-CAGGGACTTGACAGGGAAC-3′ and antisense,
5′-CCTCTCCTCGGCAAATCCT-3′; MICB sense, 5′-ACCGAG-
GACTTGACAGAGA-3′ and antisense, 5′-CCGCTGATGTTTT-
CTTCT-3′; ULBP1 sense, 5′-TCTGTGCCTCCCGCTTCTG-3′
and antisense, 5′-GCCTTGGGTTGGGTTGTGC-3′; ULBP2 sense,
5′-GCAACAAGACAGTCACACC-3′ and antisense, 5′-AGCAGGG-
GAGGATGATGAG-3′; ULBP3 sense, 5′-TCCATCGGCTTCA-
CACTCA-3′ and antisense, 5′-GTGAGGTCCAGAGCCAGGT-3′;
ULBP4 sense, 5′-CCTCCTGGGGAAGAAGGTAT-3′ and antisense,
5′-GGATTTCACTCCATTGGTGGC-3′.
Degranulation Assay
NK cell–mediated cytotoxicity was evaluated using the lysosomal
marker CD107a as previously described [19]. In brief, NK cells were
isolated from healthy donors. Drug-treated patient myeloma cells were
incubated with NK cells at an effector/target (E/T) ratio of 2.5:1 in a
U-bottom 96-well tissue culture plate with complete medium at 37°C
and 5% CO2 for 2 hours. Thereafter, cells were washed with PBS and
Figure 1. Expression of NKG2D ligands and other NK cell ligands on human myeloma cell lines and patient myeloma cells after treat-
ment with 1 mM VPA for 48 hours. (A) Selective up-regulation of MICA/B and ULBP2, without any significant effect on ULBP1, ULBP3,
and ULBP4 levels after VPA treatment on annexin V and 7AAD negative non-apoptotic ARK, OPM2, and OCI-MY5 cells. Histograms of
NKG2D ligand expression on three myeloma cell lines are shown. Gray lines represent untreated cells; blue lines represent isotype
control; purple lines represent VPA-treated cells. (B) Up-regulation of protein expression of MICA/B and ULBP2 on VPA-treated ARK,
OPM2, and OCI-MY5 cells by Western blot analysis. (C) No significant changes of expressions of other NK cell ligands, such as NKp30-L,
NKp44-L, NKp46-L, CD48, CS1, CD155, CD112, CD28, AICL(CLEC2B), and LFA-3(CD58), were seen on ARK cells after exposure to VPA.
Gray lines represent untreated cells; blue lines represent isotype control; purple lines represent VPA-treated cells. (D) Selective up-
regulation of MICA/B and ULBP2 by VPA treatment on annexin V and 7AAD negative non-apoptotic patient myeloma cells (n = 4).
Histograms of NKG2D ligand expression on patient myeloma cells are shown. Gray lines represent untreated cells; blue lines represent
isotype control; purple lines represent VPA-treated cells.
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incubated with APC-conjugated anti-CD107a (or APC-conjugated
IgG) for 45 minutes at 4°C. Cells were then stained with anti-CD3
PE or anti-CD56 FITC to gate the CD3−CD56+ NK cell population.
In some experiments, cells were pretreated with anti–NKG2D-
neutralizing mAbs or isotype control for 30 minutes at room tempera-
ture. Fluorescence was analyzed using a flow cytometer, and the data
were analyzed using FCS Express 3 Flow Cytometry software.
Cytolytic Assay
NK cell cytotoxicity against myeloma cells was analyzed using a stan-
dard 51Cr release assay at the indicated E/T ratio. Target cells were incu-
bated with VPA or control medium for 48 hours. NK cells isolated from
healthy donors were added to the target cells and incubated for 4 hours at
37°C. In blocking experiments, the blocking anti-NKG2D mAb and
mouse IgG1 as isotype control were added to the NK cells at 10 μg/ml
30 minutes before the coculture. To block perforin/granzyme-mediated
killing, we pretreated NK cells for 2 hours in 100 nM concanamycin A
(CMA; Sigma-Aldrich). To test the role of Fas-L and TRAIL-mediated
cytotoxicity, we added anti–Fas-L (5 μg/ml), anti-TRAIL (2.5 μg/ml), or
control IgG1 Ab (5 μg/ml) to effectors at the time of plating and left it in
the wells for the rest of the assay. The NK cell–sensitive cell line K562
was used as positive control. Specific lysis percentage was calculated
as (test release − spontaneous release)/(maximal release − spontaneous
release) × 100. All experiments were performed in triplicate wells.
Transfection and Plasmid
The constitutively active ERK expression plasmid was purchased
from Biovector Science Lab (Beijing, China). Plasmids included
pcDNA3.1 (empty vector) as the control and constitutively active
ERK vector (pcDNA3.1 ERK). A total of 2 × 106 ARK cells were
Figure 1. (continued).
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transfected with 2 μg of plasmid from Amaxa Nucleofection Tech-
nology (Cologne, Germany). Transfection efficiency was approximately
72% as determined using green fluorescent protein, and maximal levels
of protein expression were observed between 72 and 96 hours.
Statistical Analysis
Results of experimental points obtained from multiple experiments
were reported as means ± SD. Statistical analysis was performed using
the SPSS 15.0 software. Difference between untreated and VPA-
treated groups was performed using a paired Student’s t test. Differ-
ences among the groups were performed using one-way analysis of
variance followed by the Turkey post hoc multiple comparison tests.
A value of P < .05 was considered statistically significant.
Results
Histone Deacetylase Inhibitor VPA Induces NKG2D Ligand
Protein Expression in Patient Myeloma Cells
To investigate the effect of VPA on the surface expression of
NKG2D ligands in myeloma cells, we initially performed a flow cyto-
metric analysis by gating on annexin V and 7AAD negative non-
apoptotic ARK, OPM2, and OCI-MY5 MM cells before and after
treatment with VPA. As shown in Figure 1A, treatment of ARK,
OPM2, and OCI-MY5 cells with this inhibitor was able to upregulate
expression of MICA/B and ULBP2 without any significant effect on
ULBP1, ULBP3, and ULBP4 levels. Up-regulation of protein expres-
sion of MICA/B and ULBP2 was further confirmed by Western blot
analysis (Figure 1B). VPA treatment did not significantly affect sur-
face expression of other NK cell ligands, such as NKp30-L, NKp44-L,
NKp46-L, CD48, CS1, CD155, CD112, CD28, AICL(CLEC2B),
and LFA-3(CD58) of ARK cells, as assessed by flow cytometric anal-
ysis (Figure 1C ). Similar results were obtained by stimulating OPM2
and OCI-MY5 cells with VPA (data not shown). We next examined
the effect of VPA on the surface expression of NKG2D ligands in
patient MM cells. Increased expressions of MICA/B and ULBP2 were
observed in VPA-treated patient MM cells (Figure 1D, n = 4). Eleva-
tion of ULBP1, ULBP3, and ULBP4 expression levels following VPA
treatment was not observed in primary MM cells from four MM
patients, which is consistent with the result from MM cell lines. VPA
also did not have a significant effect on expression of other NK cell
ligands in patient MM cells (data not shown). These data showed that
HDAC inhibitor VPA is able to enhance the protein expression of
Figure 2. (A) Effect of VPA on mRNA expression of MICA on myeloma cell lines. (B) Effect of VPA on mRNA expression of MICB on
myeloma cell lines. (C) Effect of VPA on mRNA expression of ULBP2 on myeloma cell lines. (D) Effect of VPA on mRNA expression of
MICA on patient myeloma cells. (E) Effect of VPA on mRNA expression of MICB on patient myeloma cells. (F) Effect of VPA on mRNA
expression of ULBP2 on patient myeloma cells. Effect of VPA on mRNA expression of NKG2D ligands on human myeloma cell lines and
patient myeloma cells. ARK, OPM2, and OCI-MY5 cells and four patient myeloma cells were treated with 1 mM VPA for 48 hours. The
gene expression levels relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were determined using real-time PCR. Each
column and error bar represents the mean ± SD of the ratios of the NKG2D ligand mRNA level to the GAPDH mRNA level. The result
was from three independent experiments. *P < .05; #P < .01. P represents patient.
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NKG2D ligands,MICA/B andULBP2, in both myeloma cell lines and
patient myeloma cells.
VPA Induces NKG2D Ligand mRNA Expression in
Myeloma Cells
We next examined whether up-regulation of MICA/B and ULBP2
protein expressions by VPA treatment could be the consequence of
up-regulation of their mRNA expression in MM cells. We treated
ARK, OPM2, and OCI-MY5 cells with VPA, and mRNA expression
of NKG2D ligand was analyzed by real-time PCR. Upon VPA treat-
ment for 48 hours at 1 mM, a significant increase in MICA and
MICB expression ranging from 5- to 11-fold when compared with
the control was observed in the three tested MM cell lines (Figure 2,
A and B). ULBP2 mRNA expression also significantly increased in
the three cell lines (Figure 2C ). It was important to note that no
significant changes of ULBP1, ULBP3, and ULBP4 transcripts were
examined in the three tested cell lines after VPA treatment (data not
shown). Furthermore, we investigated whether treatment with VPA
had an effect on mRNA expressions of MICA, MICB, and ULBP2
in patient MM cells. Similar results were obtained by stimulating
four patient MM cells with VPA. Various degrees of up-regulation of
MICA,MICB, andULBP2mRNAexpressions were observed in patient
myeloma cells following VPA treatment for 48 hours (Figure 2, D–F ).
There was no significant change in ULBP1, ULBP3, and ULBP4 tran-
scripts in patient MM cells after exposure to VPA (data not shown).
These results strongly suggest that VPA is able to enhance MICA,
MICB, and ULBP2 mRNA expressions in human myeloma cells.
VPA Treatment Enhances NK Cell Degranulation against
Patient Myeloma Cells
To investigate whether the up-regulation of NKG2D ligand on
patient myeloma cells could lead to an activation of cytolytic NK
cells, we analyzed the degranulation of NK cells against MM cells
by evaluating the expression of the lysosomal marker CD107a on
Figure 3. Effect of VPA on NK cell degranulation against patient myeloma cells. NK cells prepared from peripheral blood mononuclear
cells (BMCs) of healthy donors were incubated with patient myeloma cells, untreated or treated with 1 mM VPA for 48 hours, used as
targets in a degranulation assay. The assay was performed at an E/T ratio of 2.5:1. After a 2-hour incubation at 37°C, cells were stained
with anti-CD56, anti-CD3, and anti-CD107a mAbs. Cell surface expression of CD107a was analyzed on CD56+CD3− NK cells by flow
cytometry. To evaluate the role of NKG2D, we performed the assay on NK cells that are in parallel treatment with blocking anti-NKG2D
Ab or isotype. Results represent two of the four patient myeloma cells.
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Figure 4. Enhanced NK cell–mediated lysis of human myeloma cell lines and patient myeloma cells following treatment with VPA. (A)
ARK cells were incubated with or without 1 mM VPA for 48 hours, then examined for their sensitivity to killing by NK cells from a healthy
donor. (B) NK cells were incubated in the presence of anti-NKG2D Abs or medium alone for 30 minutes, then used for chromium release
assay against VPA-treated ARK cells at E/T 8:1. (C, E, G, I) Primary myeloma cells from four patients were incubated with or without 1 mM
VPA for 48 hours, and the cytotoxicity of NK cells from healthy donors against patient myeloma cells was assessed by chromium release
assay. (D, F, H, J) NK cells were incubated in the presence of anti-NKG2D Abs or medium alone for 30 minutes, then used for chromium
release assay against VPA-treated patient myeloma cells at E/T 8:1. (K) The cytotoxicity assays (E/T = 8:1) were performed in the presence
and absence of the perforin inhibitor CMA (100 nM), anti–Fas-L (5 μg/ml), anti-TRAIL mAb (2.5 μg/ml), or isotype Ab (5 μg/ml) against VPA-
treated ARK cells. Data are presented as means (±SD) of triplicate samples. P represents patient. *P < .05; **P > .05.
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the effector cells by flow cytometry analysis (FACS) [19]. Purified
NK cells isolated from health donors were co-incubated with patient
myeloma cells treated with or without VPA. NK cells were triple
stained with APC-conjugated anti-CD107a mAb and with FITC-
conjugated anti-CD56 mAb together with PE-conjugated anti-CD3
mAb. A representative experiment is depicted in Figure 3. A small
percentage of NK cells expressed CD107a at the cell surface when
co-incubated for 2 hours with untreated controls. Of note, the percent-
age of CD107a+ NK cells was significantly increased upon interaction
with VPA-treated patient myeloma cells when compared with untreat-
ed controls (mean ± SD: 52.0 ± 4.2% vs 23.9 ± 2.6%, n = 4, P < .01).
The assay was performed at an E/T ratio of 2.5:1, and similar results
were obtained using different E/T ratios (data not shown). Further-
more, this increase of degranulation was considerably reduced in the
presence of a blocking anti-NKG2D mAb, whereas no significant
change of degranulation was observed upon treatment with isotype
control, suggesting that this enhancement of degranulation was de-
pendent on NKG2D activation (Figure 3). NKG2D-blocking mAb
partially affected basal degranulation, indicating that constitutive NK
cell degranulation also involves this activating receptor. Our data sug-
gest that augmented expressions of MICA/B and ULBP2 in patient
myeloma cells treated with VPA enhance NK cell degranulation by
promoting NKG2D recognition.
VPA Treatment Augments NK Cell Lysis of Myeloma Cells
through NKG2D/NKG2D Ligand Interaction
Because engagement of NKG2D receptors by MICA/B and ULBP
ligands triggers antitumor cytotoxicity of NK cells, we studied the
functional relevance of enhanced MICA/B and ULBP expressions
on ARK cells after VPA treatment. NK cells isolated from healthy
individuals were examined against ARK cells treated with or without
VPA using 51Cr release assays. NK cell lysis of the K562 cell line
was used as the positive control, and it resulted in approximately
85% lysis (E/T 8:1; data not shown). Treatment of ARK cells with
VPA showed higher sensitivity to NK cell lysis than untreated
control cells (mean ± SD: 58 ± 5% vs 32 ± 4% at E/T 8:1, P <
.05; Figure 4A). The enhancing effect of VPA was blocked by NK
cells pretreated with anti-NKG2D mAb (Figure 4B). VPA treat-
ment of myeloma cells obtained from four MM patients also signif-
icantly increased the cytotoxicity of NK cells than that of the
untreated controls. Using the same number of NK cells, the mean
lysis of VPA-treated patient myeloma cells by NK cells was 47 ± 8%
at an E/T ratio of 8:1, compared to untreated MM cells (mean ± SD:
21 ± 3%, n = 4, P < .01; Figure 4, C , E , G , and I ). Importantly, an
increase in the killing of VPA-treated patient MM cells was also
strongly reduced with the addition of anti-NKG2D mAb to the
cytolytic assay (Figure 4, D, F , H , and J ). To identify the cytotoxic
pathway used by NK cells, we examined the involvement of the
perforin/granzyme and death receptor ligand pathways. The primary
mechanism of NK cell killing of myeloma cells was perforin/granzyme-
mediated, as the perforin/granzyme inhibitor CMA greatly inhibited
killing, whereas blockings of TRAIL and Fas-L did not have a sig-
nificant impact on NK cell lysis of myeloma (Figure 4K ). A 51Cr
release assay indicated that the treatment of NK cells with VPA
did not affect their cytotoxicity against ARK cells (data not shown),
thus suggesting that NK cells can exert cytotoxicity against myeloma
cells in the presence of this drug. These findings support NK cell
activation through NKG2D/NKG2D ligand interaction as the pos-
sible mechanism involved in the increased lysis of myeloma cells
after in vitro treatment with VPA. Our data also indicated NK cells’
predominant role in the perforin/granzyme-mediated killing of
myeloma cells.
Possible Mechanism for Increased NKG2D Ligand Expression
in VPA-treated Myeloma Cells
Both ERK and AKT were shown to be involved in the regulation
of expression of NKG2D ligands [20,21]. For these reasons, both
ERK and AKT signaling pathways were studied for their constitutive
activation status in untreated ARK cells and VPA-treated ARK cells.
Western blot analysis showed a stronger constitutive pERK but not
AKT in drug-treated ARK cells than those in the untreated cells
(Figure 5A). To confirm the role of ERK signaling pathway in
NKG2D ligand expression, we performed flow cytometric analysis
and cytotoxicity assay on ERK inhibition of ARK cells and VPA-
treated ARK cells using 20 μM PD98059. Treatment of both un-
treated ARK cells and VPA-treated ARK cells with PD98059
showed only minimal effect on cell viability (data not shown). It,
however, suppressed their ERK activation status, reduced MICA/B
and ULBP2 surface expression, and impaired NK cell lysis (52.3 ±
3.2% vs 26.7 ± 2.8% for VPA-treated cells vs VPA plus PD98059-
treated cells, respectively, P < .05; Figure 5, B–E ). Exposure of VPA-
treated ARK cells to PD98059 had no effect on ULBP1, ULBP3, and
ULBP4 ligand expressions (data not shown). These results were further
confirmed by transfecting ARK cells with constitutively active ERK.
Transfection of ARK cells with constitutively active ERK resulted to
significantly higher MICA/B and ULBP2 expressions when compared
with parental ARK cells (Figure 6, A and B). It also enhanced NK cell
lysis by 2.1-fold, compared with parental ARK cells (Figure 6C ).
Furthermore, blocking NKG2D with anti-NKG2D mAb inhibited
NK cell lysis (Figure 6D). These findings suggest that increased sensi-
tivity of VPA-treated ARK cells to NK cell lysis is caused by higher
NKG2D ligand expression, resulting from more active ERK but not
AKT signaling pathway.
Discussion
Activation of the immune system, mediated by engagement of
NKG2D receptor with its ligands, plays an important role in immuno-
surveillance of cancer [22,23]. Tumor NKG2D ligand expression is
Figure 4. (continued).
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Figure 5.Mechanism of increased NKG2D ligand expression in VPA-treated ARK cells. (A) Constitutive activation of pERK in VPA-treated
ARK cells compared with that of the untreated cells is shown. The same amount of cell extracts prepared from the VPA-treated or
medium-alone cell cultures was used for Western blot analyses. (B) Western blot analysis of VPA-treated ARK cells after specific inhi-
bition of ERK activation using PD98059. Data are representative of three experiments. (C–F) MICA/B and ULBP2 expressions in VPA-
treated ARK cells after a 48-hour treatment with PD98059 (PD) using flow cytometric analysis. Histograms and mean fluorescence
intensity (MFI) levels of MICA/B and ULBP2 expressions on ARK cells are shown. Blue lines represent untreated cells; purple lines
represent VPA-treated cells; red lines represent VPA plus PD98059–treated cells. Results are representative of three different experi-
ments. Error bars indicate ±SD. (G) NK cell cytotoxicity of ARK cells treated with or without VPA after a 48-hour treatment with PD98059
or DMSO alone. Results are representative of three different experiments. Error bars indicate ±SD. *P < .05; **P > .05.
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associated with tumor eradication and increased patient survival in both
experimental animals and human cancer patients [9,23,24]. NKG2D
recognizes ligands that are often expressed at higher levels on tumor
cells than in the surrounding normal tissue and that can be induced
further by cancer treatments. Increasing evidence has shown that some
chemotherapeutic agents, such as HSP-90 inhibitors, genotoxic agents,
HDAC inhibitors, or proteasome inhibitors (e.g., bortezomib) can in-
crease the expression of NKG2D ligands, thus facilitating the activation
of NKG2D-expressing lymphocytes [including NK cells, NKT cells,
and cytotoxic T lymphocytes (CTLs)] and tumor cell lysis. Moreover,
activation of the DNA damage response by chemotherapy or radiother-
apy can also increase the expression of death receptors in several tumors,
facilitating the cytotoxic action of Fas-L– and TRAIL-positive immune
effectors on tumor cells [25–27]. Therefore, effective cancer treatments
might both directly damage tumor cells and induce NKG2D ligand
expression and subsequent attacks by killer lymphocytes. The expres-
sion of NKG2D ligand has been described in multiple types of tumor
including MM [28,29]. We investigated NKG2D ligand regulation in
human myeloma after HDAC inhibitor VPA treatment.
In this study, we found that VPA treatment induced MICA/B and
ULBP2 mRNA and protein expressions in ARK, OPM2, and OCI-
MY5 myeloma cell lines. We also found that VPA has the same effects
on MICA/B and ULBP2 mRNA and protein expressions in patients’
primary myeloma cells. However, surface expression levels of other
NK cell activating receptor ligands including NKp30-L, NKp44-L,
NKp46-L, CD48, CS1, CD155, CD112, CD28, AICL(CLEC2B),
and LFA-3(CD58) were not significantly influenced by VPA treat-
ment in ARK cells. Previously, a number of studies have shown that
Figure 6. ERK activation is responsible for increased NKG2D ligand expression. (A) ERK activation was assessed by Western blot anal-
ysis of constitutively active ERK-transfected ARK (ARK + ERK). Empty vector (EV)–transfected ARK cells (ARK + EV) were used as
control. (B) Flow cytometric analysis on NKG2D ligand expression after transfection of ARK cells with ERK. Results are representative
of three different experiments. Error bars indicate ±SD. (C) NK cell cytotoxicity experiments were performed after transfection of ARK
cells with ERK. Results are representative of three different experiments. Error bars indicate ±SD. (D) Ab blocking experiments were
performed to demonstrate the role of NKG2D/NKG2D ligand interaction in NK cell lysis after transfection of ARK cells with ERK. Results
are representative of three different experiments. Error bars indicate ±SD. *P < .05; **P > .05.
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HDAC inhibitors were able to increase expression of NKG2D ligands
in a variety of hematological and non-hematological malignant models
[8,10,15,30,31]. Kato et al. [10] found that treatment with HDAC
inhibitor trichostatin A induced MICA andMICBmRNA and protein
expressions in both lymphoid leukemic cells and myeloid leukemic
cells. Armeanu et al. [8] reported that the HDAC inhibitor VPA
induced the expression of MICA and MICB in hepatocellular carci-
noma. These results indicate that the expression of NKG2D ligands
was at least partly regulated by histone acetylation.
NKG2D ligands are induced by a wide variety of signals that have
collectively been termed “cell stress” [32–35]. DNA damage response
pathways mediated by mutated ataxia-telangiectasia (ATM) or ATM-
and Rad3-related (ATR) protein kinases have been reported to upregu-
late NKG2D ligand expression [35–37]. Gasser et al. demonstrated that
NKG2D ligand expression was induced by ATM/ATR signaling in the
DNA damage response pathway, which was prevented by ATM/
ATR inhibitors, such as caffeine [35]. Sp1 family members (also
referred to as the SP1-related retinoblastoma control proteins) have
been implicated in ULBP1, MICA, and MICB transcriptions [38–40].
López-Soto et al. proposed that the transcription is controlled by
competition between stimulatory Sp3 and repressive AP-2α transcrip-
tion factors at a cyclic adenosine monophosphate response element–like
site in the ULBP1 promoter [38]. Butler et al. demonstrated that p53
family members are important in proteasome inhibitor drug-induced
ULBP1 up-regulation in head and neck squamous cell carcinoma
[41]. The activation of the heat shock factor-1 has also been shown
to regulate MICA/B expression [39]. However, it was reported that
cell regulatory pathways such as ERK or AKT may influence NKG2D
ligand expression of leukemic cells [42–45].
To investigate the signaling pathways involved in the regulation of
NKG2D ligand expression on myeloma cells after exposure to VPA,
we focused our attention on ERK and AKT pathways. In this study,
we show for the first time, by Western blot, that VPA treatment of mye-
loma cells leads to a stronger constitutive pERK than that of the control
cells. Interestingly, we observed the increased expression of pERK1 and
the loss of pERK2 upon treatment with VPA. The underlying mecha-
nism might be due to loss of competition between ERK1 and ERK2
for their binding and activation by mitogen-activated protein kinases.
Consistent with our observations, it has been previously reported that
the ERK2 knockdown was accompanied by an increase in ERK1 phos-
phorylation in the mouse spinal cord dorsal horn [46]. Frémin et al. [47]
also observed an increase in ERK1 phosphorylation level in ERK2-
silenced rat and mouse hepatocytes. Mazzucchelli et al. [48] showed that
ERK1knockout could be accompanied by an increase in ERK2 signaling.
However, the reason for the preferential phosphorylation of ERK1 in
VPA-treated myeloma cells needs to be further investigated. Our results
also demonstrate that PD98059, the inhibitor of ERKs, blocks induction
of MICA/B and ULBP2 expressions on VPA-treated ARK cells and im-
paired NK cell lysis. Furthermore, transfecting ARK cells with constitu-
tively active ERK induced significantly higher MICA/B and ULBP2
expressions, when compared with parental ARK cells. It also increased
NK cell lysis. These findings suggest that ERK activation is involved in
the up-regulation of NKG2D ligand, leading to increased sensitivity of
VPA-treated myeloma cells to NK cell lysis. Inconsistent with our data,
ERK was also shown to increase the expression of NKG2D ligands and
the sensitivity toNK cell–mediated lysis of transformed cells derived from
solid tumors and leukemia after H2O2-induced oxidative stress [20].
The interaction between NKG2D and its ligands potentially plays
a central role in antitumor surveillance. The levels of NKG2D ligands
might determine the strength of antitumor immune responses [32,49].
Some factors, such as heat shock, transformation, and viral or bacterial
infection, have been found to regulate NKG2D ligand expression. It
has been recently shown that treatment with HDAC inhibitor induces
MICA or MICB expression on some tumor cells, rendering them more
sensitive to NK cell–mediated killing [8,10]. In our study, we also
demonstrated that the expression of activating ligands for NKG2D
in myeloma cells could be induced by HDAC inhibitor VPA, leading
to the enhancement of NK cell degranulation and an increased sus-
ceptibility of myeloma cell lines and patients’ primary myeloma cells
to the cytotoxicity of NK cells. Perforin/granzyme- and Fas-based
cytolytic pathways are two major mechanisms of cell-mediated cyto-
toxicity. We found that the primary mechanism of NK cell cytolysis
was perforin/granzyme-mediated and not through the death receptor
pathway. Moreover, this enhanced cytotoxicity was critically dependent
on the interaction between NKG2D and its ligands because it was
abolished by addition of anti-NKG2D mAb. Taken together, these
observations support the hypothesis that the induction of NKG2D
ligand expression renders myeloma cells susceptible to NK cell–
mediated killing, which can be markedly enhanced by VPA treatment.
In the present study, we demonstrated that ERK signaling pathway
was involved in VPA-induced expression of NKG2D ligands of hu-
man myeloma cells. We also provided evidence that VPA treatment
could induce expression of NKG2D ligands in myeloma cells and
consequently enhanced the sensitivity of myeloma cells to NK cell–
mediated lysis through a perforin/granzyme-mediated mechanism.
Furthermore, the increase of NK cell lytic activity was significantly
dependent on NKG2D activation. Our data suggested that the
enhancement of NKG2D ligand expressions using HDAC inhibitor
may be an attractive therapeutic strategy to induce the susceptibility
of myeloma cells to NK cell–mediated killing. The ERK pathway
leading to up-regulation of NKG2D ligands may be a productive
target for design of therapeutic agents to enhance the immunogenicity
of tumor cells.
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